Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood-derived lymphocyte therapy
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Cell Therapies
- Administration
- Intravenous
01
Overview
This experimental cellular immunotherapy, developed by the M.D. Anderson Cancer Center, consists of ex vivo expanded donor cord blood T-lymphocytes administered in combination with aldesleukin (interleukin-2). The therapy is designed for patients with relapsed hematological malignancies following an umbilical cord blood transplant. The process involves isolating T-cells from the patient's original donor cord blood unit and expanding them in a laboratory setting using anti-CD3 and anti-CD28 antibody stimulation. These expanded cells are then infused back into the patient alongside aldesleukin to enhance immune reconstitution and provide a graft-versus-leukemia (GVL) effect. This approach is particularly relevant for patients who lack access to traditional donor lymphocyte infusions from their original cord blood donor.
- Other names
- Ex vivo expanded donor cord blood T-lymphocyte infusionExpanded cord blood T-cellsDonor cord blood T-cells
Beyond the preview
Go deeper on umbilical cord blood-derived lymphocyte therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood-derived lymphocyte therapy.